. Author manuscript; available in PMC: 2020 Jul 1.

Published in final edited form as: Clin Cancer Res. 2019 Sep 26;26(1):18–24. doi: 10.1158/1078-0432.CCR-19-1483

Table 3:

Best Response by RECIST v1.1 By Tumor Type

Best response	Pancreatic Cancer n=29	Biliary Tract Cancer (n=9)	Gastroesophageal Cancer (n=6)	Unknown Primary of Suspected GI Origin (n=3)	Neuroendocrine Tumor (n=1)	HCC (n=1)	All Tumors (n=49)
Complete Response	1 (3%)	0	0	0	0	0	1 (2%)
Partial Response	9 (31%)	1 (11%)	3 (50%)	1 (33%)	0	0	14 (29%)
Stable Disease	13 (45%)	5 (56%)	2 (33%)	2 (67%)	1 (100%)	1 (100%)	24 (49%)
Disease Control	23 (79%)	6 (67%)	5 (83%)	3 (100%)	1 (100%)	1 (100%)	39 (80%)
Progressive Disease	4 (14%)	3 (33%)	0	0	0	0	7 (14%)
Not evaluable	2 (7%)	0	1 (17%)	0	0	0	3 (6%)